In 2026, supplement brands are under pressure to launch faster while maintaining quality and compliance. Latest market signals this week include: Developments in US trade policy affecting the dietary supplement industry – Regulatory Affairs Professionals Society | RAPS. The strongest teams combine AI-assisted planning with strict GMP execution.
What buyers are requesting in 2026: teams can use AI to screen combinations earlier and reduce unnecessary pilot rework.
How to validate multi-ingredient logic: claim review and release decisions must remain under qualified human regulatory control.
How OEM teams reduce reformulation risk: align formulation, procurement, and quality checkpoints for stable scale-up and consistent output.
Practical recommendation: define claim pathway before final formula lock, use AI for drafting and planning (not final approval), and keep supplier qualification, CoA checks, and release controls non-negotiable.
Final takeaway: AI is most effective in supplement manufacturing when paired with disciplined compliance systems. Reaps Pharma supports brands across formulation, pilot, and full-scale OEM manufacturing with compliance-first execution.